In July, British research service provider Envigo appointed Adrian Hardy as President and CEO. Hardy will also join Envigos Board of Directors.
US-Dutch medical device company EndoStim, developer of neurostimulation therapy for gastroesophageal reflux disease, has named Rohan Hoare as president and CEO. He succeeds founder Bevil Hogg, who will continue to serve the company as a consultant.
Antibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the companys helm for good. Kymabs new old CEO is stepping down from his role as Chairman, however.
The EMAs Committee for Medicinal Products for Veterinary Use (CVMP) has unanimously appointed David Murphy from Ireland as its new Chair for the next three years. Murphy, a qualified veterinarian, is the Veterinary Assessment Manager at the Health Products Regulatory Authority in Ireland.
Torsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy Officer.
Palma de Mallorca-based Sanifit, an expert for calcification disorders, has appointed Preston Klassen as its Chief Medical Officer. Klassen will also serve as President of Sanifits newly launched US subsidiary in San Diego.
Harriet Fear, CEO of not-for-profit One Nucleus, has been appointed a Member of the Order of the British Empire in the Queens Birthday 2016 Honours List. The award recognises her services to the life science sector.
UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the companys US business development and for establishing a team in the US.
Manchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.
After replacing several management positions over the last year, Polands leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.